A pathways company has followed up its medical and radiation oncology clinical decision tools with a new surgical oncology platform.
Clinical pathways are rapidly being adopted by providers and payers alike, to guide treatment decisions and also manage care costs. Via Oncology, a company that develops these clinical pathways using its in-house expertise of physicians, has announced the launch of a Surgical Oncology Pathways platform, which follows similar platforms for medical and radiation oncology.
In an associated press release the company said that the new platform is initially being rolled out at UPMC and Indiana University Health, for 6 diseases, incorporating key decision points for patient work-up and assessment along with surgical interventions and follow up surveillance plans.
According to Kathy Lokay, CEO and President of Via Oncology, “The Via Pathways program has been central to the quality of care in medical and radiation oncology and we are excited to expand it for use by surgical oncologists as well.”